Literature DB >> 10820244

CpG oligonucleotides are potent adjuvants for the activation of autoreactive encephalitogenic T cells in vivo.

B M Segal1, J T Chang, E M Shevach.   

Abstract

The mechanism of action of microbial adjuvants in promoting the differentiation of autoimmune effector cells remains to be elucidated. We demonstrate that CpG-containing oligodeoxynucleotides (ODN) can completely substitute for heat-killed mycobacteria in the priming of encephalitogenic myelin-reactive T cells in vivo. The adjuvanticity of the CpG ODN was secondary to their direct ability to induce IL-12 or to act synergistically with endogenous IL-12 to promote Th1 differentiation and encephalitogenicity. T cells primed in the absence of CpG with Ag and IFA alone appeared to be in a transitional state and had not undergone differentiation along a conventional Th pathway. Unlike Th2 cells, they expressed low levels of the IL-12R beta 2 subunit and retained the ability to differentiate into encephalitogenic effectors when reactivated in vitro under Th1-polarizing conditions. These results support the use of CpG ODN as adjuvants but also suggest that they could potentially trigger autoimmune disease in a susceptible individual.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10820244     DOI: 10.4049/jimmunol.164.11.5683

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  32 in total

1.  Carbohydrate-based particles: a new adjuvant for allergen-specific immunotherapy.

Authors:  Hans Grönlund; Susanne Vrtala; Ursula Wiedermann; Gerhard Dekan; Dietrich Kraft; Rudolf Valenta; Marianne Van Hage-Hamsten
Journal:  Immunology       Date:  2002-12       Impact factor: 7.397

Review 2.  Translational mini-review series on Toll-like receptors: Toll-like receptor ligands as novel pharmaceuticals for allergic disorders.

Authors:  M Goldman
Journal:  Clin Exp Immunol       Date:  2007-02       Impact factor: 4.330

Review 3.  Mycobacterium tuberculosis, autoimmunity, and vitamin D.

Authors:  Yinon Shapira; Nancy Agmon-Levin; Yehuda Shoenfeld
Journal:  Clin Rev Allergy Immunol       Date:  2010-04       Impact factor: 8.667

4.  Suppression of immune responses by nonimmunogenic oligodeoxynucleotides with high affinity for high-mobility group box proteins (HMGBs).

Authors:  Hideyuki Yanai; Shiho Chiba; Tatsuma Ban; Yukana Nakaima; Takashi Onoe; Kenya Honda; Hideki Ohdan; Tadatsugu Taniguchi
Journal:  Proc Natl Acad Sci U S A       Date:  2011-06-27       Impact factor: 11.205

5.  Plasmacytoid dendritic cells in multiple sclerosis: chemokine and chemokine receptor modulation by interferon-beta.

Authors:  Latt Latt Aung; Patricia Fitzgerald-Bocarsly; Suhayl Dhib-Jalbut; Konstantin Balashov
Journal:  J Neuroimmunol       Date:  2010-09-14       Impact factor: 3.478

Review 6.  Toll-like receptors in health and disease in the brain: mechanisms and therapeutic potential.

Authors:  Mark L Hanke; Tammy Kielian
Journal:  Clin Sci (Lond)       Date:  2011-11       Impact factor: 6.124

Review 7.  Plasmacytoid dendritic cells and immunotherapy in multiple sclerosis.

Authors:  Felipe von Glehn; Leonilda M Santos; Konstantin E Balashov
Journal:  Immunotherapy       Date:  2012-10       Impact factor: 4.196

8.  Herpes simplex virus type 1 DNA is immunostimulatory in vitro and in vivo.

Authors:  Patric Lundberg; Paula Welander; Xiao Han; Edouard Cantin
Journal:  J Virol       Date:  2003-10       Impact factor: 5.103

9.  Randomized, double-blind, placebo-controlled, safety and immunogenicity study of 4 formulations of Anthrax Vaccine Adsorbed plus CPG 7909 (AV7909) in healthy adult volunteers.

Authors:  Robert J Hopkins; Nancy F Daczkowski; Paulina E Kaptur; Derek Muse; Eric Sheldon; Craig LaForce; Suha Sari; Thomas L Rudge; Edward Bernton
Journal:  Vaccine       Date:  2013-05-10       Impact factor: 3.641

Review 10.  Toll-like receptors in central nervous system glial inflammation and homeostasis.

Authors:  Tammy Kielian
Journal:  J Neurosci Res       Date:  2006-04       Impact factor: 4.164

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.